Healthcare entity

TriGager

Technology

All 1 tracked stories fall under one category: market-trends. TriGager is most often covered alongside ATG-022, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention TriGager, all published on August 23, 2026. Each carries 2 original sources on average.

Last mentioned: 4h ago

Entity pulse

Recent coverage · TriGager

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about TriGager

All 1 tracked stories fall under one category: market-trends. TriGager is most often covered alongside ATG-022, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention TriGager, all published on August 23, 2026. Each carries 2 original sources on average.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering TriGager. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Press Release Distribution

    Company issues PRNewswire release summarizing the summit highlights.

  2. Evercore Summit Presentation

    Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.

Stories mentioning TriGager 1

Market Trends Neutral

Antengene Unveils 2 TCE Platforms, ATG-207 at China Summit

For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.

2 sources

TriGager is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.